Loading...

Akebia Therapeutics, Inc.

AKBANASDAQ
Healthcare
Biotechnology
$3.56
$-0.28(-7.29%)

Akebia Therapeutics, Inc. (AKBA) Stock Overview

Explore Akebia Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 71.8/100

Key Financials

Market Cap935M
P/E Ratio-18.58
EPS (TTM)$-0.21
ROE1.67%
Fundamental Analysis

AI Price Forecasts

1 Week$3.96
1 Month$3.66
3 Months$2.73
1 Year Target$0.11

AKBA Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Akebia Therapeutics, Inc. (AKBA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 42.72, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.11.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -18.58 and a market capitalization of 935M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Frequently Asked Questions

;